Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs
Approximately 60–70% of EWSR1 -negative small blue round cell sarcomas harbour a rearrangement of CIC , most commonly CIC-DUX4 . CIC-DUX4 sarcoma (CDS) is an aggressive and often fatal high-grade sarcoma appearing predominantly in children and young adults. Although cell lines and their xenograft mo...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2019-11, Vol.9 (1), p.15812-15812, Article 15812 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 15812 |
|---|---|
| container_issue | 1 |
| container_start_page | 15812 |
| container_title | Scientific reports |
| container_volume | 9 |
| creator | Nakai, Sho Yamada, Shutaro Outani, Hidetatsu Nakai, Takaaki Yasuda, Naohiro Mae, Hirokazu Imura, Yoshinori Wakamatsu, Toru Tamiya, Hironari Tanaka, Takaaki Hamada, Kenichiro Tani, Akiyoshi Myoui, Akira Araki, Nobuhito Ueda, Takafumi Yoshikawa, Hideki Takenaka, Satoshi Naka, Norifumi |
| description | Approximately 60–70% of
EWSR1
-negative small blue round cell sarcomas harbour a rearrangement of
CIC
, most commonly
CIC-DUX4
.
CIC-DUX4
sarcoma (CDS) is an aggressive and often fatal high-grade sarcoma appearing predominantly in children and young adults. Although cell lines and their xenograft models are essential tools for basic research and development of antitumour drugs, few cell lines currently exist for CDS. We successfully established a novel human CDS cell line designated Kitra-SRS and developed orthotopic tumour xenografts in nude mice. The
CIC-DUX4
fusion gene in Kitra-SRS cells was generated by t(12;19) complex chromosomal rearrangements with an insertion of a chromosome segment including a
DUX4
pseudogene component. Kitra-SRS xenografts were histologically similar to the original tumour and exhibited metastatic potential to the lungs. Kitra-SRS cells displayed autocrine activation of the insulin-like growth factor 1 (IGF-1)/IGF-1 receptor (IGF-1R) pathway. Accordingly, treatment with the IGF-1R inhibitor, linsitinib, attenuated Kitra-SRS cell growth and IGF-1-induced activation of IGF-1R/AKT signalling both
in vitro
and
in vivo
. Furthermore, upon screening 1134 FDA-approved drugs, the responses of Kitra-SRS cells to anticancer drugs appeared to reflect those of the primary tumour. Our model will be a useful modality for investigating the molecular pathology and therapy of CDS. |
| doi_str_mv | 10.1038/s41598-019-52143-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6825133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2311644061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-bb1e87c68a3ee04adc0c1877d4cc7bfb3415c67df1e6fa7ed413d2a1b448dfdb3</originalsourceid><addsrcrecordid>eNp9kctuFDEQRS0EIlHID7CyxIZFDF22-7VBQpMHIyIhJURiZ1W73dOOuu3Bdg_iH_hoPJmI1wJvbKlO3bquS8hLKN5AIZq3UULZNqyAlpUcpGDiCTnmhSwZF5w__eN9RE5jvC_yKXkroX1OjgRUddVU7TH5cRETdpON42xcon6gSJ3fmYmOy4yOrtYrdn73RdKIQfsZqTbTRCfrzBn9aFNAdntze0a_2TRSXJLXIZfo-uqSwQ1FnewOk_WOouvpbBLmaclquvUpj7M40eRpGg2dFreJL8izAadoTh_vE3J3efF59YFdf7par95fMy1LSKzrwDS1rhoUxhQSe11oaOq6l1rX3dCJvBpd1f0AphqwNr0E0XOETsqmH_pOnJB3B93t0s2m19lKwEltg50xfFcerfq74uyoNn6nqoaXIEQWeP0oEPzXxcSkZhv3m0Fn_BIVFwCVlEUFGX31D3rvl-Dy9x4ozqGteab4gdLBxxjM8MsMFGqftzrkrXLe6iFvtXchDk0xw25jwm_p_3T9BPnJraM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2311221972</pqid></control><display><type>article</type><title>Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs</title><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Nakai, Sho ; Yamada, Shutaro ; Outani, Hidetatsu ; Nakai, Takaaki ; Yasuda, Naohiro ; Mae, Hirokazu ; Imura, Yoshinori ; Wakamatsu, Toru ; Tamiya, Hironari ; Tanaka, Takaaki ; Hamada, Kenichiro ; Tani, Akiyoshi ; Myoui, Akira ; Araki, Nobuhito ; Ueda, Takafumi ; Yoshikawa, Hideki ; Takenaka, Satoshi ; Naka, Norifumi</creator><creatorcontrib>Nakai, Sho ; Yamada, Shutaro ; Outani, Hidetatsu ; Nakai, Takaaki ; Yasuda, Naohiro ; Mae, Hirokazu ; Imura, Yoshinori ; Wakamatsu, Toru ; Tamiya, Hironari ; Tanaka, Takaaki ; Hamada, Kenichiro ; Tani, Akiyoshi ; Myoui, Akira ; Araki, Nobuhito ; Ueda, Takafumi ; Yoshikawa, Hideki ; Takenaka, Satoshi ; Naka, Norifumi</creatorcontrib><description>Approximately 60–70% of
EWSR1
-negative small blue round cell sarcomas harbour a rearrangement of
CIC
, most commonly
CIC-DUX4
.
CIC-DUX4
sarcoma (CDS) is an aggressive and often fatal high-grade sarcoma appearing predominantly in children and young adults. Although cell lines and their xenograft models are essential tools for basic research and development of antitumour drugs, few cell lines currently exist for CDS. We successfully established a novel human CDS cell line designated Kitra-SRS and developed orthotopic tumour xenografts in nude mice. The
CIC-DUX4
fusion gene in Kitra-SRS cells was generated by t(12;19) complex chromosomal rearrangements with an insertion of a chromosome segment including a
DUX4
pseudogene component. Kitra-SRS xenografts were histologically similar to the original tumour and exhibited metastatic potential to the lungs. Kitra-SRS cells displayed autocrine activation of the insulin-like growth factor 1 (IGF-1)/IGF-1 receptor (IGF-1R) pathway. Accordingly, treatment with the IGF-1R inhibitor, linsitinib, attenuated Kitra-SRS cell growth and IGF-1-induced activation of IGF-1R/AKT signalling both
in vitro
and
in vivo
. Furthermore, upon screening 1134 FDA-approved drugs, the responses of Kitra-SRS cells to anticancer drugs appeared to reflect those of the primary tumour. Our model will be a useful modality for investigating the molecular pathology and therapy of CDS.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-52143-3</identifier><identifier>PMID: 31676869</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/1 ; 13/31 ; 13/51 ; 13/95 ; 38/32 ; 38/61 ; 38/77 ; 38/90 ; 45/23 ; 631/67/1059/602 ; 631/67/1798 ; 631/67/322 ; 631/67/70 ; 631/80/86/2368 ; 64/60 ; 82/80 ; AKT protein ; Antineoplastic drugs ; Antitumor agents ; Autocrine signalling ; Cell activation ; Cell fusion ; Chromosome rearrangements ; Drug development ; Drug screening ; FLI-1 protein ; Fusion protein ; Humanities and Social Sciences ; Insulin ; Insulin-like growth factor I ; Insulin-like growth factors ; Metastases ; Metastasis ; multidisciplinary ; R&D ; Research & development ; Sarcoma ; Science ; Science (multidisciplinary) ; Signal transduction ; Tumors ; Xenografts ; Young adults</subject><ispartof>Scientific reports, 2019-11, Vol.9 (1), p.15812-15812, Article 15812</ispartof><rights>The Author(s) 2019</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-bb1e87c68a3ee04adc0c1877d4cc7bfb3415c67df1e6fa7ed413d2a1b448dfdb3</citedby><cites>FETCH-LOGICAL-c451t-bb1e87c68a3ee04adc0c1877d4cc7bfb3415c67df1e6fa7ed413d2a1b448dfdb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825133/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825133/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27922,27923,41118,42187,51574,53789,53791</link.rule.ids></links><search><creatorcontrib>Nakai, Sho</creatorcontrib><creatorcontrib>Yamada, Shutaro</creatorcontrib><creatorcontrib>Outani, Hidetatsu</creatorcontrib><creatorcontrib>Nakai, Takaaki</creatorcontrib><creatorcontrib>Yasuda, Naohiro</creatorcontrib><creatorcontrib>Mae, Hirokazu</creatorcontrib><creatorcontrib>Imura, Yoshinori</creatorcontrib><creatorcontrib>Wakamatsu, Toru</creatorcontrib><creatorcontrib>Tamiya, Hironari</creatorcontrib><creatorcontrib>Tanaka, Takaaki</creatorcontrib><creatorcontrib>Hamada, Kenichiro</creatorcontrib><creatorcontrib>Tani, Akiyoshi</creatorcontrib><creatorcontrib>Myoui, Akira</creatorcontrib><creatorcontrib>Araki, Nobuhito</creatorcontrib><creatorcontrib>Ueda, Takafumi</creatorcontrib><creatorcontrib>Yoshikawa, Hideki</creatorcontrib><creatorcontrib>Takenaka, Satoshi</creatorcontrib><creatorcontrib>Naka, Norifumi</creatorcontrib><title>Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><description>Approximately 60–70% of
EWSR1
-negative small blue round cell sarcomas harbour a rearrangement of
CIC
, most commonly
CIC-DUX4
.
CIC-DUX4
sarcoma (CDS) is an aggressive and often fatal high-grade sarcoma appearing predominantly in children and young adults. Although cell lines and their xenograft models are essential tools for basic research and development of antitumour drugs, few cell lines currently exist for CDS. We successfully established a novel human CDS cell line designated Kitra-SRS and developed orthotopic tumour xenografts in nude mice. The
CIC-DUX4
fusion gene in Kitra-SRS cells was generated by t(12;19) complex chromosomal rearrangements with an insertion of a chromosome segment including a
DUX4
pseudogene component. Kitra-SRS xenografts were histologically similar to the original tumour and exhibited metastatic potential to the lungs. Kitra-SRS cells displayed autocrine activation of the insulin-like growth factor 1 (IGF-1)/IGF-1 receptor (IGF-1R) pathway. Accordingly, treatment with the IGF-1R inhibitor, linsitinib, attenuated Kitra-SRS cell growth and IGF-1-induced activation of IGF-1R/AKT signalling both
in vitro
and
in vivo
. Furthermore, upon screening 1134 FDA-approved drugs, the responses of Kitra-SRS cells to anticancer drugs appeared to reflect those of the primary tumour. Our model will be a useful modality for investigating the molecular pathology and therapy of CDS.</description><subject>13/1</subject><subject>13/31</subject><subject>13/51</subject><subject>13/95</subject><subject>38/32</subject><subject>38/61</subject><subject>38/77</subject><subject>38/90</subject><subject>45/23</subject><subject>631/67/1059/602</subject><subject>631/67/1798</subject><subject>631/67/322</subject><subject>631/67/70</subject><subject>631/80/86/2368</subject><subject>64/60</subject><subject>82/80</subject><subject>AKT protein</subject><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Autocrine signalling</subject><subject>Cell activation</subject><subject>Cell fusion</subject><subject>Chromosome rearrangements</subject><subject>Drug development</subject><subject>Drug screening</subject><subject>FLI-1 protein</subject><subject>Fusion protein</subject><subject>Humanities and Social Sciences</subject><subject>Insulin</subject><subject>Insulin-like growth factor I</subject><subject>Insulin-like growth factors</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>multidisciplinary</subject><subject>R&D</subject><subject>Research & development</subject><subject>Sarcoma</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Signal transduction</subject><subject>Tumors</subject><subject>Xenografts</subject><subject>Young adults</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kctuFDEQRS0EIlHID7CyxIZFDF22-7VBQpMHIyIhJURiZ1W73dOOuu3Bdg_iH_hoPJmI1wJvbKlO3bquS8hLKN5AIZq3UULZNqyAlpUcpGDiCTnmhSwZF5w__eN9RE5jvC_yKXkroX1OjgRUddVU7TH5cRETdpON42xcon6gSJ3fmYmOy4yOrtYrdn73RdKIQfsZqTbTRCfrzBn9aFNAdntze0a_2TRSXJLXIZfo-uqSwQ1FnewOk_WOouvpbBLmaclquvUpj7M40eRpGg2dFreJL8izAadoTh_vE3J3efF59YFdf7par95fMy1LSKzrwDS1rhoUxhQSe11oaOq6l1rX3dCJvBpd1f0AphqwNr0E0XOETsqmH_pOnJB3B93t0s2m19lKwEltg50xfFcerfq74uyoNn6nqoaXIEQWeP0oEPzXxcSkZhv3m0Fn_BIVFwCVlEUFGX31D3rvl-Dy9x4ozqGteab4gdLBxxjM8MsMFGqftzrkrXLe6iFvtXchDk0xw25jwm_p_3T9BPnJraM</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Nakai, Sho</creator><creator>Yamada, Shutaro</creator><creator>Outani, Hidetatsu</creator><creator>Nakai, Takaaki</creator><creator>Yasuda, Naohiro</creator><creator>Mae, Hirokazu</creator><creator>Imura, Yoshinori</creator><creator>Wakamatsu, Toru</creator><creator>Tamiya, Hironari</creator><creator>Tanaka, Takaaki</creator><creator>Hamada, Kenichiro</creator><creator>Tani, Akiyoshi</creator><creator>Myoui, Akira</creator><creator>Araki, Nobuhito</creator><creator>Ueda, Takafumi</creator><creator>Yoshikawa, Hideki</creator><creator>Takenaka, Satoshi</creator><creator>Naka, Norifumi</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191101</creationdate><title>Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs</title><author>Nakai, Sho ; Yamada, Shutaro ; Outani, Hidetatsu ; Nakai, Takaaki ; Yasuda, Naohiro ; Mae, Hirokazu ; Imura, Yoshinori ; Wakamatsu, Toru ; Tamiya, Hironari ; Tanaka, Takaaki ; Hamada, Kenichiro ; Tani, Akiyoshi ; Myoui, Akira ; Araki, Nobuhito ; Ueda, Takafumi ; Yoshikawa, Hideki ; Takenaka, Satoshi ; Naka, Norifumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-bb1e87c68a3ee04adc0c1877d4cc7bfb3415c67df1e6fa7ed413d2a1b448dfdb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>13/1</topic><topic>13/31</topic><topic>13/51</topic><topic>13/95</topic><topic>38/32</topic><topic>38/61</topic><topic>38/77</topic><topic>38/90</topic><topic>45/23</topic><topic>631/67/1059/602</topic><topic>631/67/1798</topic><topic>631/67/322</topic><topic>631/67/70</topic><topic>631/80/86/2368</topic><topic>64/60</topic><topic>82/80</topic><topic>AKT protein</topic><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Autocrine signalling</topic><topic>Cell activation</topic><topic>Cell fusion</topic><topic>Chromosome rearrangements</topic><topic>Drug development</topic><topic>Drug screening</topic><topic>FLI-1 protein</topic><topic>Fusion protein</topic><topic>Humanities and Social Sciences</topic><topic>Insulin</topic><topic>Insulin-like growth factor I</topic><topic>Insulin-like growth factors</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>multidisciplinary</topic><topic>R&D</topic><topic>Research & development</topic><topic>Sarcoma</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Signal transduction</topic><topic>Tumors</topic><topic>Xenografts</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakai, Sho</creatorcontrib><creatorcontrib>Yamada, Shutaro</creatorcontrib><creatorcontrib>Outani, Hidetatsu</creatorcontrib><creatorcontrib>Nakai, Takaaki</creatorcontrib><creatorcontrib>Yasuda, Naohiro</creatorcontrib><creatorcontrib>Mae, Hirokazu</creatorcontrib><creatorcontrib>Imura, Yoshinori</creatorcontrib><creatorcontrib>Wakamatsu, Toru</creatorcontrib><creatorcontrib>Tamiya, Hironari</creatorcontrib><creatorcontrib>Tanaka, Takaaki</creatorcontrib><creatorcontrib>Hamada, Kenichiro</creatorcontrib><creatorcontrib>Tani, Akiyoshi</creatorcontrib><creatorcontrib>Myoui, Akira</creatorcontrib><creatorcontrib>Araki, Nobuhito</creatorcontrib><creatorcontrib>Ueda, Takafumi</creatorcontrib><creatorcontrib>Yoshikawa, Hideki</creatorcontrib><creatorcontrib>Takenaka, Satoshi</creatorcontrib><creatorcontrib>Naka, Norifumi</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakai, Sho</au><au>Yamada, Shutaro</au><au>Outani, Hidetatsu</au><au>Nakai, Takaaki</au><au>Yasuda, Naohiro</au><au>Mae, Hirokazu</au><au>Imura, Yoshinori</au><au>Wakamatsu, Toru</au><au>Tamiya, Hironari</au><au>Tanaka, Takaaki</au><au>Hamada, Kenichiro</au><au>Tani, Akiyoshi</au><au>Myoui, Akira</au><au>Araki, Nobuhito</au><au>Ueda, Takafumi</au><au>Yoshikawa, Hideki</au><au>Takenaka, Satoshi</au><au>Naka, Norifumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><date>2019-11-01</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>15812</spage><epage>15812</epage><pages>15812-15812</pages><artnum>15812</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Approximately 60–70% of
EWSR1
-negative small blue round cell sarcomas harbour a rearrangement of
CIC
, most commonly
CIC-DUX4
.
CIC-DUX4
sarcoma (CDS) is an aggressive and often fatal high-grade sarcoma appearing predominantly in children and young adults. Although cell lines and their xenograft models are essential tools for basic research and development of antitumour drugs, few cell lines currently exist for CDS. We successfully established a novel human CDS cell line designated Kitra-SRS and developed orthotopic tumour xenografts in nude mice. The
CIC-DUX4
fusion gene in Kitra-SRS cells was generated by t(12;19) complex chromosomal rearrangements with an insertion of a chromosome segment including a
DUX4
pseudogene component. Kitra-SRS xenografts were histologically similar to the original tumour and exhibited metastatic potential to the lungs. Kitra-SRS cells displayed autocrine activation of the insulin-like growth factor 1 (IGF-1)/IGF-1 receptor (IGF-1R) pathway. Accordingly, treatment with the IGF-1R inhibitor, linsitinib, attenuated Kitra-SRS cell growth and IGF-1-induced activation of IGF-1R/AKT signalling both
in vitro
and
in vivo
. Furthermore, upon screening 1134 FDA-approved drugs, the responses of Kitra-SRS cells to anticancer drugs appeared to reflect those of the primary tumour. Our model will be a useful modality for investigating the molecular pathology and therapy of CDS.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31676869</pmid><doi>10.1038/s41598-019-52143-3</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2019-11, Vol.9 (1), p.15812-15812, Article 15812 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6825133 |
| source | DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | 13/1 13/31 13/51 13/95 38/32 38/61 38/77 38/90 45/23 631/67/1059/602 631/67/1798 631/67/322 631/67/70 631/80/86/2368 64/60 82/80 AKT protein Antineoplastic drugs Antitumor agents Autocrine signalling Cell activation Cell fusion Chromosome rearrangements Drug development Drug screening FLI-1 protein Fusion protein Humanities and Social Sciences Insulin Insulin-like growth factor I Insulin-like growth factors Metastases Metastasis multidisciplinary R&D Research & development Sarcoma Science Science (multidisciplinary) Signal transduction Tumors Xenografts Young adults |
| title | Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A24%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Establishment%20of%20a%20novel%20human%20CIC-DUX4%20sarcoma%20cell%20line,%20Kitra-SRS,%20with%20autocrine%20IGF-1R%20activation%20and%20metastatic%20potential%20to%20the%20lungs&rft.jtitle=Scientific%20reports&rft.au=Nakai,%20Sho&rft.date=2019-11-01&rft.volume=9&rft.issue=1&rft.spage=15812&rft.epage=15812&rft.pages=15812-15812&rft.artnum=15812&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-52143-3&rft_dat=%3Cproquest_pubme%3E2311644061%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2311221972&rft_id=info:pmid/31676869&rfr_iscdi=true |